Business Wire

TX-CIRRUS-LOGIC

25.6.2024 15:01:32 CEST | Business Wire | Press release

Share
Cirrus Logic Unveils Its Latest Additions to Its Family of Professional Audio Converters

Cirrus Logic (Nasdaq: CRUS) today unveiled the latest devices in its Pro Audio product family: a series of digital-to-analog converters (DACs) and an ultra-high performance audio CODEC that set a new standard for the prosumer and professional audio markets. These new solutions cater to the needs of recording artists, live performers, and audiophiles, delivering transparent audio converters to ensure recording and playback without any compromise in sound quality.

This launch expands on last year's successful analog-to-digital converters (ADCs) launch. Crafted with a focus on superior analog functionality and digital integration, these devices from Cirrus Logic offer exceptional performance, minimal power requirements, and innovative features like hybrid gain control, addressing longstanding audio challenges in the industry.

“True transparency in audio—that’s the hallmark of Cirrus Logic’s Pro Audio Family. It’s not just about sound, it’s about the authenticity from creation to consumption. Our commitment is purity in audio reproduction, ensuring that what you hear is as true to the original as possible,” said Eddie Sinnott, Director of Product Marketing. “With this new series of flagship audio products, we’re setting a gold standard for both professionals and prosumers, enabling our customers to create distinctive products with the confidence of our world-class engineering and support.”

Cirrus Logic CS4308P/CS4304P/CS4302P DACs and CS4282P CODEC

Designed with ease of use in mind, the Cirrus Logic Pro Audio 8-channel DAC CS4308P, 4-channel CS4304P, 2-channel CS4302P and CODEC CS4282P seamlessly integrate within a wide range of audio equipment. These new devices offer configurable advanced digital filters allowing our customers to define their signature sound. Cirrus Logic designs the devices with users in mind, making them as simple as possible to integrate and extract their full potential.

“As a long-time user of Cirrus Logic, we are excited about the new additions to its family of DAC and CODEC products being launched today,” said Simon Jones, CTO, Focusrite Group. “Cirrus Logic’s desire to keep setting the benchmark in audio quality is evident. These devices are designed to flawlessly integrate with a diverse spectrum of audio equipment, from USB audio interfaces to professional speakers and musical instruments. The addition of a hybrid gain control system into the CODEC and new ADC’s is a game changer for system integration that we really appreciate. At Focusrite, crafting audio interfaces is not just our business; it’s our passion. We bridge the gap between the artist and the audience, ensuring the sound conveyed is pristine.”

Exceptional Efficiency with Leading-Edge performance

The Pro Audio family also offers industry-leading power efficiency at 10 mW/ch for the 8/4-channel DACs, underlining Cirrus Logic’s longstanding commitment to bringing energy-efficient products to market. These new devices are 32-bit offering sample rates of up to 768 kHz, providing 129 dB of dynamic range for the CS4302P/CS4282P and 123 dB for the CS4304/8P. THD+N for these devices are all -114 dB or lower.

Product Availability

Samples of the CS4304/8P DACs and the CS4282P are available to order now. The converters are controllable and configurable using Cirrus Logic’s SoundClear® Studio software, which is available at www.cirrus.com. Samples of the CS4302P DAC will follow, later in the year.

Cirrus Logic Inc.

Cirrus Logic is a leader in low-power, high-precision mixed-signal processing solutions that create innovative user experiences for the world’s top mobile and consumer applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at www.cirrus.com.

Cirrus Logic, Cirrus and the Cirrus Logic logo are registered trademarks of Cirrus Logic, Inc. All other company or product names noted herein may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625199957/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye